Capstone Investment Advisors LLC Purchases New Holdings in BioNTech SE (NASDAQ:BNTX)

Capstone Investment Advisors LLC acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 6,541 shares of the company’s stock, valued at approximately $777,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BNTX. FMR LLC increased its position in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Candriam S.C.A. grew its position in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock valued at $25,900,000 after acquiring an additional 178,981 shares in the last quarter. Finally, abrdn plc lifted its stake in BioNTech by 334.4% during the third quarter. abrdn plc now owns 225,992 shares of the company’s stock worth $26,841,000 after purchasing an additional 173,969 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on BNTX. UBS Group boosted their target price on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Finally, HSBC upped their price objective on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Stock Up 1.8 %

Shares of BNTX stock opened at $120.72 on Friday. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average is $113.52 and its 200-day moving average is $98.35.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 earnings per share. Analysts forecast that BioNTech SE will post -3.68 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.